NCT06241469View on ClinicalTrials.gov

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 3, 2024

Primary Completion Date

August 2, 2026

Study Completion Date

February 2, 2027

Conditions
Gastric CancerGastroEsophageal CancerAdenocarcinoma
Interventions
DRUG

Sintilimab,nab-paclitaxel and tegio

Immunotherapy combined with chemotherapy

Trial Locations (1)

213004

The First People's Hospital of Changzhou, Changzhou

All Listed Sponsors
lead

Wu Jun

OTHER

NCT06241469 - Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study | Biotech Hunter | Biotech Hunter